Ana C. Garrido-Castro1, Tianyu Li2, Se Eun Kim2, Jennifer Desrosiers1, Rita Nanda3, Yara Abdou4, Amy S. Clark5, Ruth Sacks6, Thomas O’Connor1, Natalie Sinclair1, Steve Lo7, Grace Audahl1, Eileen Wrabel1, Tess O’Meara1, Tanya E. Keenan1, 8*, Nancy U. Lin1, Harold J. Burstein1, Elizabeth A. Mittendorf1, Nabihah Tayob2, Sara M. Tolaney1 SACI-IO HR+: Final results from a randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in hormone receptor-positive/HER2-negative metastatic breast cancer
, ESMO Open, 11(Supplement 4): 2026,107447
Shen J, Linn KA, Clark AS, Mamtani R, Hubbard RA. Missingness in Eligibility Criteria for Target Trial Emulation in EHR with Survival Outcomes , Stat Med, 45(8-9): 2026
Stringer-Reasor E, Li Y, Zhang J, Rocque G, Jones K, O'Sullivan C, Giridhar K, Dees EC, Nanda R, Hunter N, Clark A, Wolff A, Krop I, Lin N, Rimawi MF, Yang ES. CLO26-104: TBCRC 050: A Phase 1b/2 Trial of Niraparib and Trastuzumab in HER2+ Metastatic Breast Cancer (MBC): Safety and Efficacy
, J Natl Compr Canc Netw., 24(3.5): 2026,CLO26-104
Phun J, Clark A, Zhang J, Nayak, A. Discordant HER2 Results Highlight the Need for Compulsory Biomarker Slide Review in Breast Cancer Referrals , Laboratory Investigation, 106(3): 2026,104474
Bild AH, Sangar MC, McQuerry JA, Ideker T, Kopetz S, Carey L, Nath A, Marcus D, Regier A, Rashid N, Barzilay R, Winer E, Salgia R, Malhotra J, Gentles A, Buetow K, Mahmood F, Markman DW, Eddy JA; ADAPT Consortium. The ADAPT learning cancer treatment system: ARPA-H's initiative to revolutionize cancer therapy
, Cancer Cell, 44(3): 2026,449-454
J. Tchou, A. Nayak, H. N. Xu, J. Kollmar, E. H. Smith, M. Z. Mazur, L. Keele, A. Clark, N. Taunk, J. Fraietta, the BreastVax Study Team Abstract PS4-07-15: A single preoperative pembrolizumab dose plus a single subablative radiotherapy fraction (7 Gy) elicits anti-tumor immune response and increases stromal tumor infiltrating lymphocytes in triple negative breast cancer: a phase 1b/2 study , Clin Cancer Res, 32(4 suppl): 2026,PS4-07-15
R. Jaber Chehayeb; P. Coutifaris; F. White; J. Heintz; S. L. Jacob; J. Q. Zhang; O. M. Fayanju; E. S. Lebrow; N. Taunk; K. Lee; H. Knollman; I. Makhlin; A. Clark; R. Jankowitz; A. Nayak; S. Domchek; A. DeMichele; P. D. Shah
Factors associated with pCR and distant recurrence in patients with early-stage TNBC treated with KN522 , Clin Cancer Res, 32(4 Suppl): 2026,PS4-07-07
Pohlmann PR, Rugo HS, Yau C, Yee D, Chien AJ, Williams NO, Wallace AM, Boughey JC, Vaklavas C, Arora M, Borges V, Clark AS, Omene C, Isaacs C, Stringer-Reasor E, Nanda R, Falkson C, Albain KS, Chan N, Roussos Torres ET, Rozenblit M, Tseng J, Bommakanti S, Nangia C, Brown-Swigart L, Hirst GL, Pasricha N, Kretzer CH, Perlmutter J, Borowsky A, Symmans WF, van 't Veer LJ, Hylton N, Esserman LJ Pathologic complete response rates (pCR) after the novel HER2 ADC ARX788 in the neoadjuvant setting: Results from the I-SPY2.2 trial , Clin Cancer Research, 32(4 Suppl): 2026,PD10-02
Chien, J., Mukhtar, R.A., Yau, C., Elias, A. D., Wallace, A. M., Chan, N., Omene, C., Tseng, J., Trivedi, M. S., Stringer-Reasor, E., Yee, D., Clark, A. S., Thomas, A., Han, H., Arora, M., Nangia, C., Albain, K., Falkson, C., Isaacs, C., Zimmer, A., Rozenblit, M., van 't Veer, L., Swigart, L. B., Hirst, G. L., Symmans, W. F., Borowsky, A. D., Onishi, N., Hylton, N., Alkhafaji, S., Giridhar, K. V., Vaklavas, C., Wei, M., Goetz, M. P., Chen, N., Olopade, O., Huppert, L., Wu, C., Esserman, L. J. I-SPY2 Endocrine Optimization Pilot (EOP): Neoadjuvant vepdegestrant monotherapy or in combination with letrozole or abemaciclib in molecularly selected patients (pts) with HR+ HER2- Stage 2/3 breast cancer (BC) , Clin Cancer Res , 32(4 Suppl): 2026,PD10-02
Jung W, Ko K, Smith AM, Huang A, Xia C, Martei YM, Narayan VK, Clark AS, Lefebvre B, McDermott K, Koropeckyj-Cox D, Fasan O, Hutsell A, Daniels A, Englefield V, Leger KJ, Getz KD, Narayan HK, Marshall JD, Powell-Wiley TM, Yancy CW, Ky B. Air Pollution and Cardiac Remodeling and Function in Patients With Breast Cancer
, JAMA Netw Open, 9(1): 2026
